- REGENXBIO grants Ultragenyx exclusive, worldwide rights to NAV AAV8 and AAV9 Vectors for the development and commercialization of gene therapy treatments for a rare metabolic disorder - Agreement for use of NAV Vectors expands ongoing relationship between Ultragenyx and REGENXBIO ROCKVILLE, Md.

SARASOTA, Fla. and NOVATO, Calif. , March 16, 2020 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today

NOVATO, Calif. , March 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp , the company's Chief Financial Officer,

CFO Shalini Sharp to continue in her role until September 2020 or earlier completion of transition NOVATO, Calif. , March 03, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and

NOVATO, Calif. and TOKYO , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.  (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, and  Kyowa Kirin Co., Ltd.

NOVATO, Calif. , Feb. 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Tom Kassberg , the company’s Chief Business Officer, will

2019 total revenue is $103.7 million ; 2019 Crysvita ® (burosumab) revenue to Ultragenyx is $87.3 million 2020 Crysvita revenue in Ultragenyx territories guidance of $125 million to $140 million reaffirmed NOVATO, Calif. , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc.

NOVATO, Calif. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, February 13,

SARASOTA, Fla. and NOVATO, Calif. , Jan. 15, 2020 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that GeneTx’s

Preliminary 2019 total revenue is approximately $102 million to $104 million Preliminary 2019 Crysvita revenue to Ultragenyx of approximately $86 million to $88 million 2020 Crysvita revenue in Ultragenyx territories is expected to be in the range of $125 million to $140 million excluding EU